108 related articles for article (PubMed ID: 22835608)
21. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
22. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis.
Solomides CC; Evans BJ; Navenot JM; Vadigepalli R; Peiper SC; Wang ZX
Acta Cytol; 2012; 56(6):645-54. PubMed ID: 23207443
[TBL] [Abstract][Full Text] [Related]
24. [The expression of O6-methylguanine DNA methyltransferase and p53 in non-small cell lung cancer and the association with the prognosis].
Liu Y; Wang J; Zhang H; Fu XM; Wang HQ
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jun; 33(6):427-31. PubMed ID: 20979814
[TBL] [Abstract][Full Text] [Related]
25. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
27. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
28. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
Bozcuk H; Gumus A; Ozbilim G; Sarper A; Kucukosmanoglu I; Ozbudak IH; Artac M; Ozdogan M; Samur M; Kaya A; Savas B
Med Sci Monit; 2005 Jun; 11(6):HY11-20. PubMed ID: 15917726
[TBL] [Abstract][Full Text] [Related]
29. Prognostic relevance of altered pRb and p53 protein expression in surgically treated non-small cell lung cancer patients.
Dworakowska D; Jassem E; Jassem J; Wiedorn KH; Boltze C; Karmoliński A; Dworakowski R; Skokowski J; Jaśkiewicz K; Bosse A; Czestochowska E
Oncology; 2004; 67(1):60-6. PubMed ID: 15459497
[TBL] [Abstract][Full Text] [Related]
30. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer.
Yoshimatsu T; Uramoto H; Oyama T; Yashima Y; Gu C; Morita M; Sugio K; Kohno K; Yasumoto K
Anticancer Res; 2005; 25(5):3437-43. PubMed ID: 16101161
[TBL] [Abstract][Full Text] [Related]
31. A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.
Campayo M; Navarro A; Viñolas N; Tejero R; Muñoz C; Diaz T; Marrades R; Cabanas ML; Gimferrer JM; Gascon P; Ramirez J; Monzo M
PLoS One; 2011; 6(7):e22509. PubMed ID: 21799879
[TBL] [Abstract][Full Text] [Related]
32. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma.
Fujita Y; Fujikane T; Fujiuchi S; Nishigaki Y; Yamazaki Y; Nagase A; Shimizu T; Ohsaki Y; Kikuchi K
Cancer; 2003 Sep; 98(5):1008-13. PubMed ID: 12942569
[TBL] [Abstract][Full Text] [Related]
34. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
35. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
[TBL] [Abstract][Full Text] [Related]
36. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.
Díaz-García CV; Agudo-López A; Pérez C; López-Martín JA; Rodríguez-Peralto JL; de Castro J; Cortijo A; Martínez-Villanueva M; Iglesias L; García-Carbonero R; Fresno Vara JA; Gámez-Pozo A; Palacios J; Cortés-Funes H; Paz-Ares L; Agulló-Ortuño MT
Carcinogenesis; 2013 May; 34(5):1031-8. PubMed ID: 23349018
[TBL] [Abstract][Full Text] [Related]
37. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
39. Endothelial markers and circulating angiogenic factors and p53 may be potential markers for recurrence in surgically resected non-small cell lung cancer patients.
Brattström D; Bergqvist M; Wester K; Hesselius P; Ren ZP; Scheibenpflug L; Wagenius G; Brodin O
Med Sci Monit; 2004 Sep; 10(9):BR331-8. PubMed ID: 15328478
[TBL] [Abstract][Full Text] [Related]
40. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.
Samulin Erdem J; Skaug V; Bakke P; Gulsvik A; Haugen A; Zienolddiny S
BMC Cancer; 2016 Jan; 16():28. PubMed ID: 26780934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
